The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Open accessAbstract
Many genetic liver diseases in newborns cause repeated, often lethal, metabolic crises. Gene therapy using nonintegrating viruses such as adeno-associated virus (AAV) is not optimal in this setting because the nonintegrating genome is lost as developing hepatocytes proliferate. We reasoned that newborn liver may be an ideal setting for AAV-mediated gene correction using CRISPR-Cas9. Here we intravenously infuse two AAVs, one expressing Cas9 and the other expressing a guide RNA and the donor DNA, into newborn mice with a partial deficiency in the urea cycle disorder enzyme, ornithine transcarbamylase (OTC). This resulted in reversion of the mutation in 10% (6.7-20.1%) of hepatocytes and increased survival in mice challenged with a high-protein diet, which exacerbates disease. Gene correction in adult OTC-deficient mice was lower and accompanied by larger deletions that ablated residual expression from the endogenous OTC gene, leading to diminished protein tolerance and lethal hyperammonemia on a chow diet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result, in applications calling for corrective gene insertion, a second AAV vector encoding the sgRNA and/or a template sequence for homologydirected DNA repair must be used, reducing efficiency due to the need for cells to acquire both AAV vectors at once 59,60 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“Currently, researchers most frequently employ a dual AAV system for CRISPR-mediated gene correction: one AAV expresses Cas9 while the other expresses the sgRNA and donor template DNA [24].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
In the citing paper
“Furthermore, there was an increase in survival of mice with a high-protein diet, a stressor which exacerbates this in-born error of metabolism.”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
In the citing paper
“After AAV delivery, these mice experienced a reversion of the mutation in 10% of their hepatocytes.”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 1×
“More extensive characterization of these potential toxicities is necessary before clinical translation can be considered 24,25 , although, in animals treated as newborns, we could not detect indels of likely off-target sites at the level of sensitivity achieved by deep sequencing.”
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624 · cited 1×
“We developed a strategy using a dual-AAV system based on AAV8, which has high liver tropism to correct the point mutation in newborn spf ash mice using Cas9 enzyme from Staphylococcus aureus (SaCas9) 11–13 .”
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“Here, we leveraged our experience with liver-directed gene replacement therapy with highly hepatotropic AAV vectors 22 to move closer to realizing these goals in a model of liver metabolic disease.”
Self-citationGenome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345 · cited 1×
“Cas9 could also elicit pathologic immune responses 16 , as has been observed in gene replacement therapies in which the transgene is a foreign protein.”
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M. W., Alvira, M. R., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 335
Self-citationIn vivo genome editing of the albumin locus as a platform for protein replacement therapy
Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., Paschon, D. E., Miller, J. C., Davidson, R. J., Shivak, D., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615492 · Cited by 297
Friedland, A. E., Baral, R., Singhal, P., Loveluck, K., Shen, S., Sanchez, M. E., Marco, E., Gotta, G. M., Maeder, M. L., Kennedy, E. M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0817-8 · Cited by 285
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K. C., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M. L., et al. (2014) · Nature · doi:10.1038/nature13864 · Cited by 264
A longitudinal study of urea cycle disorders
Batshaw, M. L., Tuchman, M., Summar, M. L., & Seminara, J. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.08.001 · Cited by 210 · cited 1×
“An X-linked deficiency of the OTC enzyme in humans causes recurrent and life-threatening episodes of hyperammonemia 3,4 .”
Self-citationGene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors
Cunningham, S. C., Dane, A. P., Spinoulas, A., & Alexander, I. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.72 · Cited by 209 · cited 1×
“First, expression of the prokaryotic SaCas9 protein is transient because the non-integrated vector is lost during hepatocyte proliferation 1 .”
Robust ZFN-mediated genome editing in adult hemophilic mice
Anguela, X. M., Sharma, R., Doyon, Y., Miller, J. C., Li, H., Haurigot, V., Rohde, M., Wong, S., Davidson, R. J., Zhou, S., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497354 · Cited by 179
In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency
Mahiny, A. J., Dewerth, A., Mays, L. E., Alkhaled, M., Mothes, B., Malaeksefat, E., Loretz, B., Rottenberger, J., Brosch, D. M., Reautschnig, P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3241 · Cited by 139 · cited 1×
“One recent report in the literature approached a similar challenge by utilizing chemically modified mRNA to deliver therapeutic levels of another site-specific endonuclease into murine lung 21 .”
Precise hit: adeno-associated virus in gene targeting
Vasileva, A., & Jessberger, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1266 · Cited by 135
Yang, L., Grishin, D., Wang, G., Aach, J., Zhang, C., Chari, R., Homsy, J. G., Cai, X., Zhao, Y., Fan, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6507 · Cited by 133 · cited 1×
“More extensive characterization of these potential toxicities is necessary before clinical translation can be considered 24,25 , although, in animals treated as newborns, we could not detect indels of likely off-target sites at the level of sensitivity achieved by deep sequencing.”
Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 Vector
Wang, L., Wang, H., Bell, P. L., McMenamin, D., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.183 · Cited by 117
Self-citationHepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P. A., Hoffman, B. E., & Herzog, R. W. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 117 · cited 1×
“However, systemic delivery of AAV in a newborn helps mitigate potential immunologic adverse events for several reasons 26–28 .”
Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9
Cheng, R., Jin, P. K., Yan, Y., Cao, P., Wang, J., Qiu, C., Tang, L., Liu, D., Tang, L., Jin, J., et al. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.09.008 · Cited by 111
Hodges, P. E., & Rosenberg, L. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4142 · Cited by 102
AAV8-mediated Hepatic Gene Transfer in Infant Rhesus Monkeys (Macaca mulatta)
Wang, L., Bell, P. L., Lin, J., Calcedo, R., Tarantal, A. F., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.151 · Cited by 100 · cited 1×
“…GFP and 32 vector genomes per cell) as achieved in mice administered the same dose of GFP-expressing vector (i.e., 80% hepatocytes expressing GFP and 14 vector genomes per cell) with similar kinetics of decline, which is encouraging in terms of translation to larger species including humans 2,23 .”
Self-citationNeonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates
Hinderer, C., Bell, P., Louboutin, J.-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B. L., Bagel, J., O'Donnell, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.99 · Cited by 85 · cited 1×
“Furthermore, we have shown that exposure of newborn rhesus macaques to AAV-encoded proteins induces tolerance to these proteins, thereby circumventing toxicity caused by destructive adaptive immune responses 29 .”
Self-citationCRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 85 · cited 1×
“A key challenge in using the CRISPR/Cas9 system to correct a mutation in vivo is delivering the three components of the system (sgRNA, Cas9, and donor DNA) into the same cell in a way that is safe and efficient 19,20 .”
Clinical Outcomes of Neonatal Onset Proximal versus Distal Urea Cycle Disorders Do Not Differ
Mew, N. A., Krivitzky, L. S., McCarter, R., Batshaw, M. L., & Tuchman, M. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.06.065 · Cited by 81
Self-citationMoscioni, D., Morizono, H., McCarter, R., Stern, A., Cabrera‐Luque, J., Hoang, A., Sanmiguel, J. C., Wu, D., Bell, P. L., Gao, G., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.009 · Cited by 76 · cited 1×
“spf ash mice were maintained in an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care)-accredited and PHS (Public Health Service)-assured facility at the University of Pennsylvania, as described previously 32 .”
Self-citationWang, L., Wang, H., Morizono, H., Bell, P. L., Jones, D., Lin, J., McMenamin, D., Yu, H., Batshaw, M. L., & Wilson, J. M. (2011) · Gene Therapy · doi:10.1038/gt.2011.111 · Cited by 41
Self-citationMorizono, H., Tuchman, M., Rajagopal, B. S., McCann, M. T., Listrom, C. D., Yuan, X., Venugopal, D., Bárány, G., & Allewell, N. M. (1997) · Biochemical Journal · doi:10.1042/bj3220625 · Cited by 39 · cited 1×
“OTC enzyme activity was assayed in liver lysates as described previously with modifications 35 .”
Self-citationDevelopment of the Ornithine Cycle in Rat Liver: Zonation of A Metabolic Pathway
Dingemanse, M. A., de Jonge, W. J., de Boer, P. A. J., Mori, M., Lamers, W. H., & Moorman, A. F. M. (1996) · Hepatology · doi:10.1002/hep.510240219 · Cited by 27
Nivsarkar, M. S., Buckley, S. M. K., Parker, A. L., Perocheau, D. P. B., McKay, T. R., Rahim, A. A., Howe, S. J., & Waddington, S. N. (2015) · Journal of Immunology Research · doi:10.1155/2015/397879 · Cited by 14
Shi, Y., Falahati, R., Zhang, J., Flebbe-Rehwaldt, L., & Gaensler, K. M. L. (2013) · Gene Therapy · doi:10.1038/gt.2013.22 · Cited by 13
AAV-Mediated Gene Transfer to the Liver
Daly, T. M. (2004) · Humana Press eBooks · doi:10.1385/1-59259-650-9:195 · Cited by 12 · cited 1×
“Newborn (postnatal day 2, p2) male pups received a temporal vein injection of the mixture of two vectors at the intended doses for each in a volume of 50 μl, as described 33 .”
Augustin, L. B., Mavinakere, M. S., Morizono, H., & Tuchman, M. (2000) · Pediatric Research · doi:10.1203/00006450-200012000-00023 · Cited by 11 · cited 1×
“OTC protein was detected by a custom rabbit polyclonal antibody (1:10,000 dilution) 34 .”
Self-citation
Research works printed but not linked: 1
- Lichter-Konecki, U., Caldovic, L., Morizono, H. & Simpson, K. Ornithine transcarbamylase deficiency (1993–2013). in GeneReviews (eds. Pagon, R.A. et al.) http://www.ncbi.nlm.nih.gov/books/NBK154378/ (29 August 2013).
Cited by
Sorted by citations
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2016) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,037
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Metadata
- Authors
- Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., Batshaw, M. L., & Wilson, J. M.
- Affiliations
- Sichuan University (CN)
- University of Pennsylvania (US)
- Children's National (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Wilson, James M
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2016-02-01
- Volume
- 34
- Issue
- 3
- Pages
- 334-338
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4786489
- OpenAlex
- W2253584908
- Cited by
- 556
- References
- 36
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 36 · 2023: 52 · 2022: 55 · 2021: 61 · 2020: 70 · 2019: 62 · 2018: 72 · 2017: 71 · 2016: 30
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01HD057247)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, CRISPR/Cas9, gene correction, ornithine transcarbamylase deficiency, urea cycle disorders, neonatal mice, liver disease, hyperammonemia, high-protein diet, hepatocytes, gene therapy
- MeSH terms
- Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Ornithine Carbamoyltransferase, Viruses, RNA Editing, Gene Transfer Techniques, Ornithine Carbamoyltransferase Deficiency Disease, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
